Entries by Business Wire

Early Findings with KEYTRUDA, Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

PHILADELPHIA–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs. The early findings presented showed an […]

,

Peloton Therapeutics Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting

DALLAS & PHILADELPHIA–(BUSINESS WIRE)–Peloton Therapeutics Inc., a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities, presented preclinical data on its lead investigational candidate, PT2385, at the American Association for Cancer Research Annual Meeting in Philadelphia, PA. PT2385 is the first clinical stage antagonist of hypoxia inducible […]

Epizyme Announces Closing of Common Stock Offering

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Epizyme. The underwriters purchased 701,448 shares from Epizyme at […]

FDA Approves Only ICD with Ultra-High Energy on the First Shock

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today that the Food and Drug Administration (FDA) has approved the only implantable cardioverter defibrillator* (ICD) that can deliver ultra-high energy on the first shock. Also included in the approval response from the FDA is the latest generation of defibrillator devices for patients with complex heart […]

,

IBM Acquires Heritage Group Portfolio Company Explorys

Explorys, a portfolio company of venture capital firm Heritage Group, has been acquired by IBM in an agreement signed April 13. In May 2012, big data company Explorys received a significant investment from the Heritage Healthcare Innovation Fund, a $167 million strategic venture fund that invests in businesses that reduce healthcare costs, improve outcomes and increase […]

Biogen Shoots Up Following Positive RENEW Results for Anti-LINGO-1

– First evidence of treatment-related remyelination in the human central nervous system –   – Ongoing SYNERGY trial will further inform potential for anti-LINGO-1 in MS –   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study […]

Pfizer Beams As Cancer Drug Efficacy Stops Trial Early and Analysts Predict Game Changer

4/15/2015 8:43:44 AM Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy  Phase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that […]

,

OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation

BERLIN–(BUSINESS WIRE)–OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were Vesalius Biocapital II S.A. SICAR, acting as lead; a SMS Group Company; VC […]

Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study to demonstrate remyelination (the formation of new myelin on axons) following an inflammatory injury in humans. These data will be presented at the 67th Annual Meeting of the […]